WELCOME TO PARI PHARMA!

The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.

We are currently working with both the eFlow Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol Delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.

Thursday, 13. December 2007

PARI’s eFlow delivers Alnylam RNAi Therapeutic in Phase I study

 

PARI’s eFlow delivers Alnylam RNAi Therapeutic in Phase I study

Monterey, Calif., December 13, 2007 – PARI’s eFlow, an advanced electronic nebulizer,...

 

Monday, 26. November 2007

PARI’s eFlow included in Gilead’s NDA Submission for Aztreonam Lysine for Inhalation

 

 

PARI’s eFlow included in Gilead’s NDA Submission for Aztreonam Lysine for Inhalation

Monterey, California, November 26, 2007 – PARI Pharma’s eFlow...

 

Monday, 24. September 2007

Pediatric Asthma Programs featuring PARI Pharma’s eFlow

 

Pediatric Asthma Programs featuring PARI Pharma’s eFlow

Acquired by AstraZeneca

MONTEREY, CALIFORNIA, SEPTEMBER 24, 2007 – Today, the rights to Verus...

 

Thursday, 14. June 2007

PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference

 

PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference

MUNICH, GERMANY, JUNE...

 

Tuesday, 29. May 2007

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis

 

Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients with Cystic...